680 related articles for article (PubMed ID: 19803762)
1. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
2. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
3. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
4. Clinical peptide vaccination trials for leukemia patients.
Casalegno-Garduño R; Schmitt A; Schmitt M
Expert Rev Vaccines; 2011 Jun; 10(6):785-99. PubMed ID: 21692700
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccines for leukemia patients.
Schmitt A; Hus I; Schmitt M
Expert Rev Anticancer Ther; 2007 Mar; 7(3):275-83. PubMed ID: 17338648
[TBL] [Abstract][Full Text] [Related]
6. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
7. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic peptide vaccination with leukemia-associated antigens.
Rusakiewicz S; Molldrem JJ
Curr Opin Immunol; 2006 Oct; 18(5):599-604. PubMed ID: 16870418
[TBL] [Abstract][Full Text] [Related]
9. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.
Greiner J; Bullinger L; Guinn BA; Döhner H; Schmitt M
Clin Cancer Res; 2008 Nov; 14(22):7161-6. PubMed ID: 19010831
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia.
Alsabti EA; Taleb AM; Raji HM; Kalil OZ; Saleh KA
Jpn J Exp Med; 1979 Jun; 49(3):157-68. PubMed ID: 385948
[TBL] [Abstract][Full Text] [Related]
12. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
Klammer M; Roddie PH
Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
[TBL] [Abstract][Full Text] [Related]
13. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
[TBL] [Abstract][Full Text] [Related]
14. [Allogeneic stem cell transplantation in the management of acute myeloid leukemia].
Schmid C; Kolb HJ
Med Klin (Munich); 2007 Apr; 102(4):317-23. PubMed ID: 17426935
[TBL] [Abstract][Full Text] [Related]
15. Vaccination for leukemia.
Molldrem JJ
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.
Lodewyck T; Cornelissen JJ
Blood Rev; 2008 Nov; 22(6):293-302. PubMed ID: 18455284
[TBL] [Abstract][Full Text] [Related]
17. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
19. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
[TBL] [Abstract][Full Text] [Related]
20. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
Loren AW; Porter DL
Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
